From the drug-ingredient-target-pathway network, the top 10 core compounds and 4 NAFLD-related targets (LKB1, AMPK, PPARα, CPT1A) were selected (Table 2). This evidence concerns the gene CPT1A and metabolic dysfunction-associated steatotic liver disease.